BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $47,000 | +2.2% | 570 | 0.0% | 0.06% | -8.2% |
| Q1 2019 | $46,000 | +21.1% | 570 | 0.0% | 0.06% | -16.4% |
| Q4 2018 | $38,000 | -13.6% | 570 | 0.0% | 0.07% | +65.9% |
| Q3 2018 | $44,000 | +4.8% | 570 | 0.0% | 0.04% | 0.0% |
| Q2 2018 | $42,000 | +13.5% | 570 | 0.0% | 0.04% | +4.8% |
| Q1 2018 | $37,000 | 0.0% | 570 | 0.0% | 0.04% | 0.0% |
| Q4 2017 | $37,000 | +2.8% | 570 | 0.0% | 0.04% | -2.3% |
| Q3 2017 | $36,000 | -99.9% | 570 | 0.0% | 0.04% | +7.5% |
| Q2 2017 | $34,599,000 | +16.8% | 570 | 0.0% | 0.04% | +8.1% |
| Q1 2017 | $29,634,000 | +16.3% | 570 | 0.0% | 0.04% | +37.0% |
| Q4 2016 | $25,474,000 | +91.1% | 570 | +103.6% | 0.03% | +58.8% |
| Q3 2016 | $13,328,000 | +5.3% | 280 | 0.0% | 0.02% | 0.0% |
| Q2 2016 | $12,662,000 | +10.1% | 280 | 0.0% | 0.02% | +6.2% |
| Q1 2016 | $11,502,000 | +7.7% | 280 | 0.0% | 0.02% | +23.1% |
| Q4 2015 | $10,682,000 | +16.1% | 280 | 0.0% | 0.01% | +8.3% |
| Q3 2015 | $9,198,000 | -53.0% | 280 | 0.0% | 0.01% | -45.5% |
| Q2 2015 | $19,580,000 | +2.1% | 280 | 0.0% | 0.02% | -4.3% |
| Q1 2015 | $19,180,000 | -6.5% | 280 | 0.0% | 0.02% | -14.8% |
| Q4 2014 | $20,521,000 | – | 280 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |